Liraglutide, sold under the brand name Victoza among others, is an anti-diabetic medication used to treat type 2 diabetes, and chronic obesity. It is a second-line therapy for diabetes following first-line therapy with metformin. Its effects on long-term health outcomes like heart disease and life expectancy are unclear. It is given by injection under the skin.
Liraglutide is a glucagon-like peptide-1 receptor agonist also known as incretin mimetics. It works by increasing insulin release from the pancreas and decreases excessive glucagon release.
